TriangleLetrozole (NCT05649956)
Letrozole trial for Uterine Leiomyosarcoma (NCT05649956). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with stage I uterine leiomyosarcoma, estrogen-receptor staining above ten percent, and no measurable disease after hysterectomy and removal of both ovaries and tubes within twelve weeks.
The idea: letrozole blocks aromatase, reducing estrogen production. Patients are randomized to a daily 2.5-milligram oral dose or observation. Researchers test whether this delays progression or death over three years. Current chemotherapy or radiation and aromatase-inhibitor use within five years exclude participation.
This phase 2 study plans 40 patients. Bradley Corr chairs the GOG Foundation study; thirty-four US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.